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ABSTR ACT: Celiac sprue is a chronic disease, which usually occurs in children and young adults. However, it can develop in any age group, and the 
prevalence is increasing even in the elderly population. The atypical patterns of clinical presentation in this age group sometimes can cause a delay in 
diagnosis. Given the lower sensitivity and specificity of serological tests in the aged population, clinical suspect often arises in the presence of complications 
(autoimmune disorders, fractures, and finally, malignancy) and must be supported by endoscopic and imaging tools. In this review, we highlight the 
incidence and prevalence of celiac disease in the elderly, the patterns of clinical presentation, diagnosis, and the most frequent complications, with the aim 
of increasing awareness and reducing the diagnostic delay of celiac disease even in the elderly population.
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Introduction
Celiac disease (CD) is an immune-mediated enteropathy 
caused by a reaction to gliadin, a protein fraction contained in 
wheat and other common grains such as barley and rye. It has 
been traditionally recognized in children and young adults, 
although, recently, detection in the elderly population has 
increased.1,2 Studies report that about 25% of celiac patients 
were first diagnosed in the seventh decade in several countries, 
such as Canada, United States, and Northern Europe.3–5
Usually, when onset of CD occurs in adulthood or in 
elderly, patients can present either with gastrointestinal (GI) 
symptoms, such as diarrhea, bloating and steatorrhea, or more 
frequently with weight loss and selective malabsorption of 
nutrients, such as iron, calcium, and fat-soluble vitamins (A, 
D, E, and K). Other patterns of clinical presentation, in this 
age group, can be autoimmune diseases and malignancies, the 
latter supposed to be related to a longer exposure to the harmful 
effects of gluten6–9 as compared to other age groups (Table 1).
In this review, we highlight the incidence and prevalence 
of CD in the elderly, the patterns of clinical presentation, 
diagnosis, and the most frequent complications, with the aim 
of increasing awareness and reducing the diagnostic delay of 
CD even in the elderly people.
Incidence and Prevalence
Nowadays, there is a growing incidence of CD diagnosis 
among adults, particularly in the elderly.10 The incidence of 
CD in the age group over 65 years has gradually increased 
from 4% to 19%–34%.11,12
A large survey conducted in the United States showed that 
the rate of diagnosis of CD among the elderly (age . 65 years 
old) was similar to that in the age group 0 to 18 years (16% 
versus 15%, respectively).13
Currently, the estimated prevalence of CD is about 1% 
in the general population, although previous data have shown 
that it was 0.71% around 1990, in the United States,4 which 
was lower than that in Europe (Italy and Sweden).14–16 Later 
on, Fasano et al,17 in a multicenter study of serological screen-
ing for CD, showed that the occurrence of CD among adults 
was approximately 1.2%. In addition, authors have also shown 
that positive seroprevalence for undetected CD in individu-
als aged between 45 and 76 years was 1.2%. The same epi-
demiological scenario has been found in a Finnish study, in 
which the seroprevalence and biopsy-proven diagnosis of CD 
in persons aged between 52 and 74 years was around 2.1%.18 
Another study by Lohi et al demonstrated that CD can be 
first diagnosed in the elderly population, despite the apparent 
tolerance of gluten ingestion for the entire life.19
Pathogenesis
Both innate and adaptive abnormal immune responses against 
gluten in CD patients are caused by pro-inflammatory envi-
ronment expressed by a massive intraepithelial infiltration 
and the appearance of the characteristic crypt hyperplasia and 
villous atrophy,20,21 which leads to the clinical manifestations 
of the disease. The adaptive immune response mainly acts in 
the lamina propria of the intestinal mucosa while the innate 
immune response preferentially involves the epithelial layer. 
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Dendritic cells (DCs) presenting antigen lead to the outcome 
(pro-inflammatory or tolerogenic) of antigen-specific immune 
responses. In addition, DCs promote the maintenance of 
immune tolerance toward nutrients and commensals, but at due 
time, they initiate immune responses toward invading patho-
gens.22 Following gluten peptide deamination by the enzyme 
tissue transglutaminase (tTG),23 DCs submit peptides through 
the MHC-II molecules, including human leucocyte antigen 
(HLA)-DQ2 or HLA-DQ8, performing antigen presentation 
to CD4+-naïve T-cells. Consequently, T-cell response is glu-
ten-specific Th1/Th17 pro-inflammatory T-cells, resulting in 
a disruption of the oral tolerance to gluten. These T-cells pro-
duce a bulk of pro-inflammatory cytokines, including inter-
feron-g (IFN-g), tumor necrosis factor-a (TNF-a), IL-18, and 
IL-21,24–26 which stimulate other immune cells to the intestine 
establishing a positive pro-inflammatory feedback that leads 
to tissue damage. Probably, the first trigger of the mucosal 
lesion is the IL-15 production by intraepithelial lymphocytes 
(IEL) following gluten exposure,27,28 which would lead to an 
increased epithelial permeability indirectly, weakening the 
tight junctions between the IECs but also directly inducing 
intestinal epithelial cells (IEC) apoptosis. This would favor 
the transport of gluten peptides to the lamina propria where 
IL-15-activated DCs would recognize gluten peptides (follow-
ing their deamination by the tTG), hence initiating the sec-
ondary antigen-specific adaptive immune response responsible 
for the clinical manifestations of the disease.29
Although there are a large amount of data about the 
immunological mechanism inside the pathogenesis of CD, 
little is known about the association between CD and auto-
immune disease.30 Predominant and not mutually exclusive 
hypotheses include the presence of a linkage disequilibrium of 
genes that generally predispose to autoimmune diseases,31 the 
modification of permeability of intestinal barrier,32 an altered 
microbiome,33 and posttranslational modifications of immu-
nogenic peptides.34
Association with other autoimmune disorders is relevant 
either because of a detrimental effect on the clinical burden of 
CD (and vice versa) or because symptoms of secondary auto-
immunity can be the sole presentation of CD. In fact, in a 
large number of cases, both in adults and children, the disease 
remains clinically silent and the only manifestation is associ-
ated diseases.35,36 The typical example is CD diagnosis upon 
screening after diagnosis of type 1 diabetes or thyroid diseases. 
Gene polymorphisms associated with CD are also typically 
related to biological pathways common to other autoimmune 
diseases, as well as with genes involved in the triggering of pro-
inflammatory responses.37 Indeed, although the IFN-g gene 
has not been related to CD pathogenesis, it has been described 
that 15 CD susceptibility genes, which approximately repre-
sent 30% of the total described genes associated with CD, reg-
ulate the increased mRNA expression levels of IFN-g found in 
the CD mucosa, while it has also been suggested that all such 
genetic polymorphisms would not only be related to Th pro-
inflammatory responses (including the Th1, Th2, and Th17 
pathways) but also to B-cell phenotype and function.38
Patterns of Clinical Presentation
The clinical spectrum of CD is widely variable, from severe 
and generalized malabsorption with important weight loss to 
nutritional deficiency of a single nutrient such as iron or cal-
cium, thus configuring the clinical picture of iron deficiency 
anemia and severe osteopenia or osteoporosis.39 The reason 
of which, in the elderly the GI pattern of presentation is less 
common than in younger adults, is unknown; however, in the 
aged population, deficiency of micronutrients may often rep-
resent the only symptom at presentation.40
However, CD occurs more frequently in women as 
compared with men, with a female to male ratio of 2:1. By 
contrast, in the elderly, CD is much more diagnosed in men, 
as compared with women, in whom the incidence increases till 
the age of 65 years and then starts to decline. GI symptoms, 
when present in the elderly, are mild, making the diagnosis 
difficult. Diarrhea, weight loss, and abdominal pain are more 
commonly indicative of irritable bowel syndrome in the elder 
patient than CD.41 In fact, although CD is the most common 
cause of steatorrhea in people over 50 years of age, malab-
sorption is well tolerated in people over 65 years.42 Diarrhea is 
mild or intermittent, and occasionally, the elder celiac patient 
can present with constipation.43 In addition, celiac patients 
could present to a physician with an autoimmune disease, such 
as hypothyroidism, or with a malignancy, such as lymphoma; 
in this case, CD might be present without symptoms, as silent 
celiac disease.
Up to 80% of elderly patients with CD in a British series 
presented with anemia, mainly due to iron deficiency.11,44 
However, deficiency of folic acid and vitamin B12 may also be 
responsible of anemia in these patients, which sometimes can 
Table 1. differences regarding clinical presentation, serology, 
histology, associated disease, complications, and response to gFd 
between young and elderly onset Cd.
YOUNGER CD ELDERLY CD
Clinical 
presentation
anemia, statural 
growth impairment
anemia, micronutrients 
deficiency
diarrhea Constipation, steatorrea
Weight loss obesity
serology/histology high titers low titres
Marsh 3 Marsh 1–2
associated 
disease
type 1 diabetes osteopenia
thyroid disease neurologic disorders
Migraine Cardiovascular disease
Complications rare refractory celiac disease
non-hodgkin’s lymphoma
response to gFd
adherence to gFd
Fast slow
high adherence low adherence
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be detected through alterations in the peripheral smear.45,46 
It has been suggested that inflammation may also be the cause 
of anemia, and in this regard, it has been shown that celiac 
patients sometimes have raised serum levels of ferritin and 
erythrocyte sedimentation rate, suggesting a systemic inflam-
matory state.47
Lack of calcium and vitamin D are consequences of mal-
nutrition, leading to a decrement in bone mass, which contrib-
utes to the risk of fractures, especially in elder patients who 
are already predisposed to bone metabolism disorders.83,84 
In  addition to the above-mentioned clinical problems com-
ing from malabsorption of iron, calcium, and vitamin D, mal-
nutrition can be responsible of hypoalbuminemia, which can 
further lead to hypocalcemia and hypomagnesemia, as well. 
Peripheral edema and ascites may be clinical signs of reduction 
in serum albumin. In about 20% of celiac patients, abnormal 
liver function tests can be present; this condition is already 
known as “celiac hepatitis”. Peripheral edema, ascites, and 
hypoalbuminemia associated with alteration of aminotrans-
ferases may be responsible for further investigation to exclude 
a chronic liver disease, but in these patients, gluten-free diet 
(GFD) has beneficial effects on the resolution of symptoms 
and regression of liver function test abnormalities.48
In addition to GI symptoms and malabsorption syn-
drome resulting from bowel involvement, CD can also be 
diagnosed through associated autoimmune disease and/or 
complications (Table 2).
One of the most frequent complications of CD is der-
matitis herpetiformis, a skin manifestation, characterized by 
pruritus and papulovesicular eruptions involving the surfaces 
of elbows, knees, buttocks, and scalp.49 Sometimes, it can be 
the only presentation of gluten intolerance, occurring in about 
25% of celiac patients, mostly men, with an age of presentation 
ranging from 40 to 70 years. The diagnosis is performed by 
biopsy of the perilesional areas and the subsequent direct 
immunofluorescence of the sample, showing granular deposi-
tion of IgA in the dermal–epidermal junction. GFD is able to 
resolve the clinical picture even if slowly.50–52
CD can also be associated with mucosal collagen diseases 
(collagenous colitis),53 as well as lymphocytosis of the stomach, 
colon, and biliary tract.54–56 In some patients, collagenous 
colitis may be the first clue to diagnose CD,57 or may present 
as a complication of CD causing diarrhea apparently refractory, 
although the patient is on GFD.
Another frequent modality of presentation of CD are 
autoimmune disorders, sharing with CD association with 
peculiar HLA haplotypes, occurrence of autoantibodies, mul-
tiorgan involvement, and finally dysregulation of immune 
responses.58–61 Knowledge of the risk of an autoimmune dis-
ease in celiac patients leads to better management of patients, 
and some investigators have reported that the risk of develop-
ing an autoimmune disease is directly related to the age at 
diagnosis, as far as the duration of gluten exposure.62
Hashimoto’s thyroiditis and Graves’ disease are the most 
frequent immune-mediated thyroid disorders affecting celiac 
elder patients.63,64 In the elderly, hypothyroidism has a high 
prevalence, whereas type 1 diabetes presents a low prevalence.65
Autoimmune liver disease, such as autoimmune hepatitis, 
biliary cirrhosis, and sclerosing cholangitis, can also affect 
celiac patients. In these cases, liver involvement is quite dif-
ferent from celiac hepatitis; thus, patients do not benefit from 
GFD, but from immunosuppressive therapy.66
Neurological complications of CDs are ataxia and 
neuropathy; the treatment of which can be very problematic67–69 
because equilibrium disorders increase the risk of falls, and 
thus, the risk of bone fractures, which is already high for the 
low density of the bone mass of these patients.
Serological and Histological Diagnosis
The diagnosis of CD in elderly patients follows the same 
guidelines as in young people. Diagnosis is based on the pres-
ence of anti-gliadin antibodies (AGAs), endomysial antibod-
ies (EMAs), or tissue transglutaminase antibodies (tTGAs). 
Moreover, the presence of intraepithelial lymphocytosis, 
villous atrophy, crypt hyperplasia, and the response to GFD 
are also used for diagnosis. Titer of tTGAs and improvement 
of histological lesions are inversely related to age.70 This clinical 
and histological lower expression in adults and elder patients 
make the diagnosis more complex as compared with children.
The European Society of Pediatric Gastroenterology and 
Nutrition have formulated guidelines for the diagnosis of CD 
in children based on high tTGA titers without the need for 
duodenal biopsy.71 This is based on evidence of elevated anti-
body titers that have a high predictive value for villous atrophy, 
thus avoiding the need for a biopsy. However, the presence of 
high antibody titers (.10 times normal levels) appears in less 
than half of the adult cases.72 Serological test, such as tTG 
IgA, has a high sensitivity (~90%) and specificity (~95%) 
as compared to that of EMA. The TTG IgA evaluation is 
Table 2. rates of symptoms at presentation and complications in Cd 
of the elderly.
PRESENTATION/COMPLICATION FREQUENCY REFERENCE 
anemia 60–80% 47
osteopenia/bone disease 70% 83
Malabsorption 50–80% 41
dermatitis herpetiformis 25% 52
Celiac hepatitis 20% 1
Collagenous sprue 20% 57
autoimmune thyroiditis 15% 63
ataxia and neuropathy 15% 67
refractory Cd 5% 96
idiopathic dilated cardiomyopathy 5,7% 122
t cell lymphoma 4% 98
type 1 diabetes 3% 47
Cappello et al
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recommended as serological screening test for adult CD 
patients, since AGAs have a low sensitivity and specificity.73 
The use of deamidated gliadin peptides (DGPs) as antigens 
has proven to be much more accurate than the standard AGA 
test.73–75 In spite of a good sensitivity and specificity of the 
above reported tests, a certain number of patients with CD 
cannot be diagnosed on the basis of serology. EMA test, tTG, 
and DGPs have more false-negative results in patients with 
mild histological lesions.74,76 Another case of negative test in 
celiac patient is the deficit of IgA; in this context, IgG isotype 
of antibodies that are significantly more sensitive compared to 
tTG IgG can be used.74–76
When there is a clinical suspicion of CD, despite nega-
tive serology, patients must be submitted to GI endoscopy to 
obtain biopsy.74,77 Duodenal biopsy specimens are commonly 
used to show the presence of enteropathy. The rise of infiltrat-
ing intraepithelial lymphocyte, crypt hyperplasia, and grade 
of villous atrophy (partial or total) are the main histological 
features of CD.78 Recent studies have shown that in more 
than 50% of adults, villous atrophy does not improve on GFD 
unless biopsy is performed after two years of an adequate 
diet.79 In children, even if information are limited, the recov-
ery of the mucosa occurs in the vast majority (95%) in the first 
two years after diagnosis.75 There are age-dependent changes 
in the bowel of elder patients, and therefore, histological diag-
nosis of CD can differ from that of younger patients.13,41,80 
One might delay the intestinal biopsy to an elder patient with 
comorbidity to confirm the CD suspicion, but often the elder 
individual is more likely to have an endoscopy to investigate 
GI symptoms; then, it is often more common to have a histo-
logical diagnosis rather than serological. HLA testing would 
be essential in these seronegative patients.76,78
From a clinical point of view, diagnosing CD in the 
elderly is quite difficult, not only for family doctors but also for 
gastroenterologists. In fact, very often, patients present mild 
clinical symptoms, and if this is associated with a low level 
of suspicion of CD in older people, clinical examination will 
be carried out to confirm or rule out more serious conditions 
(such as malignancy).76 Moreover, the fragility of older patient 
means that sometimes they are subject to mood disorders and 
their bowel habits may depend on these changes, especially in 
patients suffering from irritable bowel syndrome, or, in addi-
tion, may be due to aging process. Because of these reasons, 
older patients with CD often have an average diagnostic delay 
of about 15–17 years.13,81 In addition, a sign such as anemia in 
the elderly is highly suspicious of colon cancer rather than CD. 
Other diseases (bacterial overgrowth syndrome, intestinal 
ischemia, and exocrine pancreatic insufficiency) may present 
with malabsorption syndrome, and mimic CD may or occur 
in celiac patients because of their advanced age, as well. Thus, 
a complete and accurate differential diagnosis is the basis of 
the diagnostic process, leading to CD in the elderly.43,82
Complications
Bone disease and fractures. Bone diseases are mainly 
due to intestinal malabsorption. The reduction in bone mass is 
the most common metabolic bone disorder in CD. Up to 70% 
of adults and elderly patients with CD have a bone mineral 
density that is less than one standard deviation below normal 
controls (osteopenia).83 Postmenopausal women are affected 
more often than those in premenopause.84
The mechanism for osteopenia may be related, in part, 
to the malabsorption of calcium, causing an increase in the 
secretion of parathyroid hormone. The increased bone turn-
over leads to the loss of cortical bone. A decreased absorption 
of vitamin D could be also experienced by CD patient. Pro-
inflammatory and anti-inflammatory cytokines are believed to 
play an active role in the pathogenesis of osteopenia in CD.
Osteotropic cytokines are involved in bone remodeling 
because they regulate the differentiation and activation of 
osteoblasts and osteoclasts; TNF-a and IFN-g are two cyto-
kine issues during chronic inflammation, and they are associ-
ated with increased bone loss. In patients with untreated CD, 
higher levels of serum cytokines that directly trigger osteo-
clasts (IL-1, IL-6, and TNF-a) have been detected, while 
low levels of cytokines that play an inhibitory role (IL-18 and 
IL-12) are observed.85,86 The receptor activator of nuclear fac-
tor kappa-B ligand (RANKL) is basic for bone homeostasis 
by a dynamic balance between bone-reabsorbing activity per-
formed and the effects of its natural decoy receptor osteopro-
tegerin (OPG). OPG/RANKL ratio is significantly lower in 
individuals with CD with recovery of intestinal mucosa than 
in healthy controls and is positively correlated with low bone 
mineral density.87 Potential autoantibodies could block the 
inhibitory effect of OPG on RANKL; however, in another 
study,88 antibodies against OPG were not found in the serum 
of patients with CD.
Although celiac patients can improve bone mineral 
density on GFD, the increase in bone mass in the elderly is 
limited and may be incomplete. A higher prevalence of frac-
tures also occurs in the peripheral skeleton of elderly celiac.89 
Most fractures happen before the diagnosis of CD and com-
monly occur in those with poor compliance to GFD. Diet is 
the most important factor that offers protection from the risk 
of fracture. In a recent population-based study on the long-
term fracture risk,90 CD has been linked to an increased risk 
of fractures before and after diagnosis. Axial and appendicular 
fractures are a good rationale for early diagnosis of CD and 
active management of bone disease before the fractures occur.
Refractory celiac disease. Refractory celiac disease 
(RCD) is characterized by severe malabsorption in a patient 
with histological lesions showing lack of response to GFD, 
despite firm adherence to the diet. The main reason for lack 
of response to diet is gluten contamination.91 In the elderly, 
other diseases, such as exocrine pancreatic insufficiency, 
bacterial overgrowth syndrome, and lactose intolerance, are 
involved in the differential diagnosis of RCD,91,92 as well as 
Elderly onset celiac disease 
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enteritis, collagen sprue, and intestinal mucosa damage from 
anti-inflammatory drugs.93,94
Patients complain severe malabsorption, progressive 
weight loss, and significant deficiencies of nutrients and electro-
lytes. Depending on the phenotype of intraepithelial lympho-
cytes, the RCD can be classified into two types: polyclonal, or 
RCD I, and monoclonal with aberrant phenotype of lympho-
cytes, or RCD II.95 Celiac patients develop an RCD in about 
4%–5% of cases, the majority of them being older people. In a 
study conducted in Mayo Clinic,96 which included 57 patients 
with RCD with a variable age ranging from 30 to 76 years, 
it was found that the average age for diagnosis of RCD I and 
RCD II was 58 and 70 years, respectively. At five years, over-
all survival was 80% and 45% for patients with RCD I and 
RCD II, respectively; the main causes of death were refractory 
state (in RCD I) and enteropathy-associated T-cell lymphoma 
(in RCD II).97,98 In patients with lymphoma, the prognosis was 
poor. They also found that old age (greater than 65 years) was 
one of the prognostic factors with negative effect on the sur-
vival in the new staging system proposed for the RCD.96
It should be pointed out that persistent mucosal altera-
tions are common in adult celiac on a GFD and that follow-up 
biopsies should be done only after two years of diet to docu-
ment the histological recovery,79 suggesting that the label 
of refractory can be applied only after a long period (Figs. 1 
and 2). Mucosal alterations in RCD are classic endoscopic 
signs of villous atrophy such as loss of Kerckring’s folds in 
the duodenum, scalloping of circular folds, and fissuring with 
a mosaic pattern. These findings are not specific for RCD. 
The diagnosis of RCD requires a combination of clinical and 
pathologic findings. Indeed, the diagnosis is made on the 
basis of strong evidence of CD, supplemented with systematic 
exclusion of both other causes of nonresponsive CD or villous 
atrophy and malignancy. Although RCD is a diagnosis of 
exclusion, it is supported by objective findings in laboratory 
and histological studies. Duodenal histology shows partial 
villous atrophy and an increased number of intraepithelial 
lymphocytes with normal immunophenotype characterized 
by expression of CD3 and CD8 (type 1 RCD) or duodenal 
biopsy specimen from a patient with type 2 RCD with villous 
Figure 1. endoscopic duodenal view of a 73-year-old patient with rCd.
Figure 2. RCD in the 73-year-old patient: small intestinal mucosal biopsy with frank villous atrophy, showing mild chronic inflammatory infiltrate and some 
eosinophils in the lamina propria (A/B; hematoxylin/eosin 20× and 40×); Cd3 immunostaining highlights an increased number of intraepithelial Cd3+ 
lymphocytes (C/D 20× and 40×).
Cappello et al
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atrophy and abnormal intraepithelial lymphocytes character-
ized by expression of CD3, but mostly CD8−.99
Malignancy. Occurrence of malignancy is higher in 
elder celiac patients, particularly in those with age ranging 
from 60 to 80 years. In fact, T-cell lymphomas have been 
reported to have the strongest association with CD (Fig. 3). 
Further, the relative risk for lymphoma in CD has been showed 
to be varying in several studies.100 Lymphoma occurs usu-
ally after 60 years of age and sometimes starts with ulcerative 
lesions, explaining the high rate of free perforation in these 
patients; ulcerative lesions and perforation often appear with 
the beginning of chemotherapy. Lymphomas and adenocarci-
nomas are more frequent in patients with CD,101 even those 
presenting with silent disease showed a higher mortality rate.102 
GFD seems to have a protective effect on the risk of malig-
nancy in celiac patients.103 In a series of 119 patients with pri-
mary small-bowel non-Hodgkin’s lymphoma (NHL), at least 
13 (10.9%) were associated with CD.104 Treatment with a GFD 
may ameliorate the prognosis of these cases, eg, by improving 
the nutritional status and the absorption of drugs given orally.105
Celiac Disease and Cardiovascular Risk
Although cardiovascular manifestations play a secondary role 
in CD in comparison with autoimmune diseases, it seems 
that being celiac confers an increased risk of death due to 
cardiovascular events.106,107 In fact, it has been shown that 
individuals with CD are considered at increased risk of death, 
and other studies107 have shown an increased risk of inci-
dent ischemic heart disease, death resulting from ischemia, 
or cardiovascular disease. Furthermore, one of these studies 
reported a twofold increased risk of coronary artery disease in 
patients with CD,107 whereas risk of angina and heart failure 
were raised to 30%–40%. However, it has been estimated that 
the incidence of cardiovascular disease in patients affected by 
CD is overall about 5.7%.106 In an important study of CD 
screening, carried out on 52 subjects affected by idiopathic 
dilated cardiomyopathy,123 3 out of 52 patients (6%) showed 
an intestinal villous atrophy. An Italian study108 including 
187 patients, 110 with heart failure and 77 with arrhyth-
mias, for whom a diagnosis of autoimmune myocarditis had 
been performed, 4.4% were positive to EMAs and tTGAs, 
as compared to 0.6% of healthy controls. Another study 
is particularly interesting in this regard, since it identifies 
QT interval prolongation in one-third of the celiac patients 
studied, in comparison with no alteration in patients suffer-
ing from chronic pancreatitis and other intestinal disorders.109 
In patients with CD, an inverse relationship between QT 
interval prolongation and blood potassium has been found, 
hence the recommendation to supplement the diet therapy 
with potassium administration. The average daily KCl and 
spironolactone dose was 3.5 ± 1.2 mg/kg.110
The biological mechanisms linking CD, chronic heart 
failure, and other cardiovascular conditions are not fully 
understood, but several possible pathways have been sug-
gested. One of these could be linked to the evidence that 
CD patients have a low-grade chronic inflammation, which 
could drive atherosclerosis and vascular damage.111 Further-
more, patients following a GFD do not always eat a healthy 
balance of fats, carbohydrates, and fibers,112,113 contributing 
to the pathogenesis of atherosclerotic process. Regarding this, 
a case–control study114 showed that CD is associated with an 
increased intima-media thickness of the carotid arteries, a 
well-known intermediate marker of endothelial dysfunction 
and macrovascular disease.
A further hypothesis linking CD and cardiac damage is 
the autoimmune mechanism triggered by gliadin, as already 
showed for other autoimmune disorders associated with 
CD.115 Furthermore, the favorable effect of a GFD shows 
that the improvement in cardiac function may be due to an 
enhanced absorption of nutrients and oligoelements, playing a 
beneficial role on myocardial contractility and electrical stabil-
ity, as well as cardiovascular drug absorption. However, there 
is also evidence that tTG antibodies have an anti-angiogenic 
effect116–118 that may alter the normal functioning of the vascu-
lar system. However, CD, when untreated or when the adher-
ence to a GFD is poor, could lead to malabsorption of nutrients 
and thus low circulating concentrations of folate or high serum 
concentrations of homocysteine,119 which are implicated in 
the pathology of cardiovascular disease.120,121 In fact, villous 
atrophy can hinder the absorption of several nutrients, such as 
thiamin, riboflavin, magnesium, calcium, selenium, and car-
nitine, which are active in myocardial metabolism. In particu-
lar, an increment in carnitine levels can be effective for cardiac 
performance, as some authors have already observed in patients 
with CD and dilated cardiomyopathy treated with a GFD.122
Figure 3. Ct scan showing wall thickening of some jejunal loops (arrows) 
with associated hyperdensity of mesenteric fat of a Cd patient with t-cell 
lymphoma, anaplastic large cells. eatl was initially diagnosed in 2009, 
when the patient underwent surgery because of obstruction. at this time, 
diagnosis of Cd was not established for limited extension of mucosal 
damage on the surgical specimen, although the high level of clinical 
suspicion (but negative serology). six years later, during follow-up, a new 
endoscopy was performed and finally a diagnosis of CD was formulated 
(small intestinal mucosal biopsy showed Marsh 3B; intraepithelial 
lymphocytes (Cd3+) .25/100).
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However, regarding the incidence of risk factor for car-
diovascular disease among celiac patients, it has been previ-
ously observed that mortality due to ischemic heart disease 
and stroke123 was lower than that in the general population, 
thereby hypothesizing a protective action of CD against the 
above-mentioned conditions, maybe because of the low levels 
of cholesterol, triglyceride, and fibrinogen. Recently, a nation-
wide population cohort study124 carried out on 3790 celiac 
patients effectively confirmed a reduction in the risk of hyper-
tension and hypercholesterolemia, and thus of myocardial 
infarction, but showed a slight increase in the risk of stroke.
Therefore, available evidence suggests that cardiovascular 
manifestations can also be reported in CD. Thus, patients suf-
fering from cardiovascular disease, and especially idiopathic 
dilated cardiomyopathy, could be reasonable to suspect CD, 
given the evident favorable effect caused by a GFD on myo-
cardial performance.
Final Remarks
Despite a paucity of symptoms, such as diarrhea and weight 
loss, CD has been increasingly recognized in the elderly. 
Other presentations in the elderly age group include iron 
deficiency anemia (often refractory to oral iron), autoim-
mune disorders, bone disease due to osteopenia, including 
fractures, malignant intestinal disease, especially lymphoma, 
and finally idiopathic dilated cardiomyopathy. Diagnosis 
may be delayed due to limited symptoms, a low index of 
clinical suspicion, or diagnostic difficulties related to impor-
tant cognitive impairment that often affects elderly people. 
Although for these patients, the GFD is the key of clinical 
management, elderly patients sometimes are scarcely adher-
ent to diet.
Patients should be referred to specialists to ensure the 
better management of the disease and related complications. 
Micronutrients, such as iron, calcium, vitamin D supplemen-
tation, and vitamins, should be part of a modified GFD for 
the elderly patients. All other therapeutical interventions that 
limit malabsorption and avoid complications should be con-
sidered part of a management strategy.
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